Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01529268

Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children — CyNCh  

Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trial

Official title:
Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children (CyNCh)

Clinical Trial Summary

CyNCh is a multi-center, placebo-controlled clinical trial of children ages 8 to 17 years with biopsy-confirmed moderate to severe nonalcoholic fatty liver disease (NAFLD). The primary objective is to evaluate whether 52 weeks of treatment with cysteamine bitartrate delayed-release capsules will result in improvement in liver disease severity.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01529268
Study type Interventional
Source National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact
Status Completed
Phase Phase 2/Phase 3
Start date June 2012
Completion date September 2015
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02244944 - Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD Phase 2
Recruiting NCT01544751 - Nonalcoholic Fatty Liver Disease (NAFLD) Pharmacological Treatment: Metformin Versus Atorvastatin N/A
Recruiting NCT03572465 - Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis
Enrolling by invitation NCT04059029 - Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients
Terminated NCT01930123 - Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance Biomarkers in Nonalcoholic Fatty Liver Disease Phase 2
Recruiting NCT01705522 - Multimodal Approach in IBD Patients
Recruiting NCT03525769 - Screening With FibroTouch for Advanced Liver Fibrosis in NAFLD Patients With Underlying Type 2 Diabetes
Completed NCT01265498 - The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT) Phase 2
Completed NCT02217345 - Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease Phase 2
Completed NCT03486899 - A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis Phase 2
Completed NCT02781584 - Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) Phase 2
Completed NCT03486912 - A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis Phase 2
Completed NCT02196831 - Tesamorelin Effects on Liver Fat and Histology in HIV N/A
Withdrawn NCT03451279 - A Nonabsorbable Ileal Apical Sodium-Dependent Bile Acid Transporter Inhibitor for Nonalcoholic Steatohepatitis Phase 2
Completed NCT02044523 - Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound
Completed NCT03836443 - Postprandial Lipotoxicity and Nonalcoholic Fatty Liver Disease N/A
Completed NCT03042767 - Anti-LPS Antibody Treatment for Pediatric NAFLD Phase 2
Recruiting NCT02213224 - Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Phase 4
Completed NCT03459079 - Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease Phase 2
Not yet recruiting NCT06024408 - A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor Phase 1